clarithromycin
clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
Cross Reference
Introduction
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with clarithromycin?
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (63)
- J. Antimicrob. Chemother. (56)
- J. Clin. Microbiol. (39)
- Others (258)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with clarithromycin
PubChem Associated disorders and diseases
What pathways are associated with clarithromycin
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with clarithromycin?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
- J. Antimicrob. Chemother. (25)
- Antimicrob. Agents Chemother. (20)
- J. Clin. Microbiol. (9)
- Others (66)
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with clarithromycin?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with clarithromycin?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with clarithromycin?
Related references are published most in these journals:
- J. Antimicrob. Chemother. (20)
- Antimicrob. Agents Chemother. (17)
- J. Clin. Microbiol. (13)
- Others (57)
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with clarithromycin?
Mouse Model
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Related references are published most in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Antimicrob. Chemother. (1)
- Clin. Diagn. Lab. Immunol. (1)
- Others (2)
| Model | Cross reference | Weighted score | Related literatures |
|---|
NCBI Entrez Crosslinks
All references with clarithromycin
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Adamek RJ et al. | Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection. | 1995 | Am. J. Gastroenterol. | pmid:7801936 |
| Jaup BH and Norrby A | Low dose, short-term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7771426 |
| Ives DV et al. | Impact of clarithromycin and azithromycin on patterns of treatment and survival among AIDS patients with disseminated Mycobacterium avium complex. | 1995 | AIDS | pmid:7755914 |
| Klapper SR et al. | Atypical mycobacterial infection of the orbit. | 1995 | Ophthalmology | pmid:9097803 |
| Ostroff SM et al. | Preventing disseminated Mycobacterium avium complex disease in patients infected with human immunodeficiency virus. | 1995 | Clin. Infect. Dis. | pmid:8547516 |
| Odagiri S | Levofloxacin in patients with severe respiratory tract infection. | 1995 | Drugs | pmid:8549387 |
| Logan RP et al. | Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. | 1995 | Aliment. Pharmacol. Ther. | pmid:8527618 |
| Gill CJ et al. | In vivo evaluation of three acid-stable azalide compounds, L-701,677, L-708,299 and L-708,365 compared to erythromycin, azithromycin and clarithromycin. | 1995 | J. Antibiot. | pmid:7490222 |
| Spangler SK et al. | Susceptibilities of 201 anaerobes to erythromycin, azithromycin, clarithromycin, and roxithromycin by oxyrase agar dilution and E test methodologies. | 1995 | J. Clin. Microbiol. | pmid:7615756 |
| Michałowska-Mitczuk D | [Patients with chronic sputum positive tuberculosis-a therapeutic problem]. | 1995 | Pneumonol Alergol Pol | pmid:7633360 |
| Colizza DF | Pertussis update. | 1995 | J Sch Health | pmid:7637337 |
| de Boer WA and Tytgat GN | The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? | 1995 | Scand. J. Gastroenterol. | pmid:7638563 |
| Takimoto T et al. | Efficacy of lansoprazole in eradication of Helicobacter pylori. | 1995 | J. Clin. Gastroenterol. | pmid:7594327 |
| Shimoyama T et al. | Eradication of Helicobacter pylori with lansoprazole and clarithromycin in gastric ulcer patients. | 1995 | J. Clin. Gastroenterol. | pmid:7594328 |
| Fukuda Y et al. | Combination therapies with a proton pump inhibitor for Helicobacter pylori-infected gastric ulcer patients. | 1995 | J. Clin. Gastroenterol. | pmid:7594330 |
| Xu G et al. | [Effect of clarithromycin on macrophage functions]. | 1995 | Kansenshogaku Zasshi | pmid:7594777 |
| Gelber RH et al. | Activity of combinations of dapsone, rifampin, minocycline, clarithromycin, and sparfloxacin against M. leprae-infected mice. | 1995 | Int. J. Lepr. Other Mycobact. Dis. | pmid:7602221 |
| Milde P et al. | Cutaneous bacillary angiomatosis in a patient with chronic lymphocytic leukemia. | 1995 | Arch Dermatol | pmid:7543264 |
| Nightingale SD et al. | Clarithromycin-induced mania in two patients with AIDS. | 1995 | Clin. Infect. Dis. | pmid:7548513 |
| Matsiota-Bernard P et al. | Mycobacterium genavense infection in a patient with AIDS who was successfully treated with clarithromycin. | 1995 | Clin. Infect. Dis. | pmid:7548515 |
| Tamaoki J et al. | Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus. | 1995 | J. Allergy Clin. Immunol. | pmid:7722166 |
| Conte JE et al. | Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:7726492 |
| Labenz J and Börsch G | Toward an optimal treatment of Helicobacter pylori-positive peptic ulcers. | 1995 | Am. J. Gastroenterol. | pmid:7733070 |
| Forné M et al. | Impact of colloidal bismuth subnitrate in the eradication rates of Helicobacter pylori infection-associated duodenal ulcer using a short treatment regimen with omeprazole and clarithromycin: a randomized study. | 1995 | Am. J. Gastroenterol. | pmid:7733075 |
| Tebas P et al. | Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. | 1995 | Clin. Infect. Dis. | pmid:7742453 |
| Teare JP et al. | Pseudomembranous colitis following clarithromycin therapy. | 1995 | Eur J Gastroenterol Hepatol | pmid:7743311 |
| Pollak PT et al. | Delirium probably induced by clarithromycin in a patient receiving fluoxetine. | 1995 | Ann Pharmacother | pmid:7655131 |
| Ozmen MM and Johnson CD | Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication? | 1995 | Am. J. Gastroenterol. | pmid:7661197 |
| Schlossberg D | Azithromycin and clarithromycin. | 1995 | Med. Clin. North Am. | pmid:7791424 |
| Gross RH et al. | Corneal pharmacokinetics of topical clarithromycin. | 1995 | Invest. Ophthalmol. Vis. Sci. | pmid:7706046 |
| Frotz H et al. | [Ranitidine and clarithromycin for eradication of Helicobacter pylori in patients with duodenal ulcer]. | 1995 | Arzneimittelforschung | pmid:7710445 |
| Luna-Herrera J et al. | Antituberculosis activity of clarithromycin. | 1995 | Antimicrob. Agents Chemother. | pmid:8593004 |
| Ellis LC et al. | Postantibiotic effect of clarithromycin alone and combined with ethambutol against Mycobacterium avium complex. | 1995 | Antimicrob. Agents Chemother. | pmid:8593025 |
| Truffot-Pernot C et al. | Clarithromycin is inactive against Mycobacterium tuberculosis. | 1995 | Antimicrob. Agents Chemother. | pmid:8593032 |
| Schütze K and Hentschel E | Duodenal ulcer healing after 7-day treatment: a pilot study with lansoprazole, amoxicillin and clarithromycin. | 1995 | Z Gastroenterol | pmid:8600661 |
| Rizzato G et al. | Efficacy of a three day course of azithromycin in moderately severe community-acquired pneumonia. | 1995 | Eur. Respir. J. | pmid:7789484 |
| Labenz J et al. | High-dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. | 1995 | Digestion | pmid:7895926 |
| Reid R et al. | Pneumococcal meningitis during therapy of otitis media with clarithromycin. | 1995 | Pediatr. Infect. Dis. J. | pmid:8786899 |
| Van Asselt GJ et al. | Susceptibility of Streptococcus pyogenes to azithromycin, clarithromycin, erythromycin and roxithromycin in vitro. | 1995 | J. Med. Microbiol. | pmid:7563004 |
| Cheng B | Preventing opportunistic infections. | 1995 | PI Perspect | pmid:11362422 |
| Abbott files SNDA for MAC prophylaxis. | 1995 | J Int Assoc Physicians AIDS Care | pmid:11362606 | |
| Cohen Y et al. | Use of normal C57BL/6 mice with established Mycobacterium avium infections as an alternative model for evaluation of antibiotic activity. | 1995 | Antimicrob. Agents Chemother. | pmid:7793882 |
| Pierce M | Another perspective on MAC prophylaxis. Interview by Gordon Nary. | 1995 | J Int Assoc Physicians AIDS Care | pmid:11362746 |
| Furney SK et al. | Activities of rifabutin, clarithromycin, and ethambutol against two virulent strains of Mycobacterium avium in a mouse model. | 1995 | Antimicrob. Agents Chemother. | pmid:7793895 |
| Archange YR et al. | Clarithromycin prophylaxis against disseminated Mycobacterium avium complex in patients with AIDS. | 1995 | J Int Assoc Physicians AIDS Care | pmid:11362747 |
| Brown BA et al. | Clarithromycin-induced hepatotoxicity. | 1995 | Clin. Infect. Dis. | pmid:7795060 |
| Physician's aggressive preventive therapy differs. | 1995 | AIDS Alert | pmid:11362774 | |
| Raffi F et al. | Breakthrough cerebral toxoplasmosis in patients with AIDS who are being treated with clarithromycin. | 1995 | Clin. Infect. Dis. | pmid:7795062 |
| New drug applications sought. | 1995 | AIDS Alert | pmid:11362777 | |
| Sharma PK and Tami TA | AIDS: lessons from the last decade and prospects for the future. | 1995 | Ear Nose Throat J | pmid:7796740 |